Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use DALIRESP safely and effectively. See full prescribing information for DALIRESP. DALIRESP® (roflumilast) tabletsInitial U.S. Approval: 2011
Medication labelWhy this: Advisory · dailymed-prescription
DALIRESP® is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm. DALIRESP 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose.
- generic_name
- roflumilast
- product_names
- roflumilast
- ndc
- 0310-0095, 0310-0095-30, 0310-0095-90, 0310-0095-39, 0310-0095-95, 0310-0088, 0310-0088-39, 0310-0088-28, 0310-0088-95
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en